Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Flow ⢠High Profitability ⢠Rising Leverage IDXX combines exceptional profitability and cash conversion with manageable debt service, but its elevated valuation, rising leverage, and limited liquidity warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Last-month decline ⢠Oversold momentum ⢠Key support test Support Level: $505â$510 Resistance Level: $515â$520 IDXX remains in a last-month downtrend but is oversold near $505â$510 support; watch for stabilization above $520, while a break below $505 signals further downside.
Sentiment & News
Key News Insights: ⢠Raised EPS outlook ⢠CoVetAI acquisition ⢠Mixed stock signals IDEXX's stronger 2026 EPS outlook, recurring diagnostics growth, and CoVetAI expansion support long-term momentum, though recent share weakness and FX/inventory risks warrant caution.
AI Summary
IDEXX is shifting from a premium veterinary-diagnostics growth story to a recurring workflow-and-data platform whose valuation now depends on proving diagnostics penetration, pricing, and software/AI can offset declining U.S. clinic visits; investors should wait for evidence of demand stabilization and sustained growth above $535â$540 before treating the selloff as a durable entry point.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |